Skip to content

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

Sep 2026 · Cancer Research · 0 citations

TL;DR

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States with a dismal 5-year survival rate of 13%. More than 90% of pancreatic tumors are driven by oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS). Mutation-specific and pan-RAS inhibitors have shown great promise in ongoing clinical trials, but primary and acquired resistance is common. It is therefore critical to understand how these inhibitors impact the tumor immune microenvironment to inform how these drugs can potentially be combined with immunotherapies. To understand the direct effect of RAS inhibition on T cells, an orthotopic PDAC mouse tumor model with inducible and reversible pancreas epithelial cell-specific oncogenic KRAS expression was generated. Mice were either implanted with inducible KRAS (iKRAS) tumor cells or basement membrane extract control and administered doxycycline to induce KRAS G12D expression. A 25-color spectral flow cytometry panel was generated to understand the impact of pharmacologic and genetic RAS inhibition on infiltrating T cells. With this we were able to characterize differences in the composition of tumor-infiltrating T cells and in the activation, memory, and exhaustion status of CD8+ and CD4+ T lymphocytes across these test conditions. In addition, we ran the same panel on liver tissue to study potential changes in a pre-metastatic niche. As expected, both genetic inactivation of KRAS (RAS-OFF) and pharmacologic inhibition of RAS (RASi) reduced the tumor burden compared to the untreated control (RAS-ON). We did not observe differences in the total proportion of T cells (%CD3+ of CD45+) within the tumor. However, expansion of effector T cells within the CD8+ T cell compartment was only observed in the RAS-OFF condition within the pancreatic tumor microenvironment. A higher frequency of terminally exhausted CD8+ T cells was also noted in the RAS-OFF mice compared to the RASi and RAS-ON conditions, further highlighting discrepancies in the differentiation of these cells upon RAS inhibition. In the liver, the phenotype of CD8+ T cells treated with RAS inhibitor was similar to that of RAS-OFF. Additionally, while no differences were observed in the frequency of regulatory T cells (%Foxp3+ of CD4+) in tumors, a lower proportion of regulatory T cells was noted in the liver, indicating potential tissue specific differences. Together, these findings suggest that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche. Future studies will investigate the mechanisms underlying these phenomena to inform new therapeutic combinations for PDAC. Lauren Gerbereux, Rashmi Kumar, Emily Lasse-Opsahl, Carlos Espinoza, Thejaswini Giridhara, Megan Procario, Hannah Watkoske, Shelby Stakenas, Allison Bischoff, Marina Pasca di Magliano, Timothy Frankel. Impact of RAS inhibition on T cell maturation in the PDAC microenvironment [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B087.

View source

Similar papers

Sep 2026

Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing

Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...

Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al. · 0 citations
Sep 2026

Abstract B074: Comparative analysis of next-generation KRAS inhibitors in patient derived pancreatic cancer organoids

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a five-year survival rate below 10%. Due to aggressiveness and lack of early detection methods, patients are often diagnosed at an advanced stage, leaving few therapeutic options. This emphasizes the need for a deeper understanding of the mo...

P. Winckler, Georg Vladimirov, Lennart Herrlich et al. · 0 citations
Sep 2026

Abstract IA003: Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy

Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy holds significant translational potential as KRAS inhibitors are poised to become a mainstay in PDAC treatment and treatment induced antigens may serve as the foundation for rationally designed combination immunotherapies.

Alex M. Jaeger, Emma Adhikary, Andrew Deonarine et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations
Sep 2026

Abstract B053: RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade and combining anti-PD-(L)1 therapy with standard-of-care chemotherapy has not improved clinical outcomes over chemotherapy alone. Because oncogenic RAS drives both tumor growth and tumor-intrinsic immune suppression, we h...

L. Grigoryan, Keith Macaraig, Victor Batiste et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.